NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
AstraZeneca
Teva Branded Pharmaceutical Products R&D, Inc.
Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd